source
- STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.STAT · 3mo ago↗ source
- European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyDrug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…Endpoints · 3mo ago↗ source
- Amgen launches late-stage obesity trial in patients who switch from rival drugsAmgen is launching three new late-stage trials for its long-acting obesity shot MariTide, including one designed to test the drug in patients switching away from Eli Lilly and Novo Nordisk's blockb…